Testing for ERBB2/HER2 has paved the way for precision oncology in breast cancer. However, the complexity of HER2 biology is evident in other solid tumor cancers, including non-small cell lung cancer. All three types of HER2 alterations could appear in NSCLC, including mutations, amplifications, and overexpression. HER2 mutations represent distinct oncogenic drivers, and next-generation sequencing is an ideal method for detecting them due to its heterogeneity.
Please fill out this form to download our guide with information about molecular profiling for HER2 mutations in NSCLC.